Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01563302 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01563302 is a Phase 1 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 64 participants.
The verdict
NCT01563302, a Phase 1 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of patients with advanced cancers. Eligible patients with DLBCL or other advanced lymphomas will be enrolled into the dose-expansion cohort.
Interventions
- DRUG IONIS-STAT3Rx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2012-02-27 |
| Est. Completion | 2016-03-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01563302
The ClinicalTrials.gov registry entry for NCT01563302 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IONIS-STAT3Rx is the first listed.
NCT01563302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01563302 about?
NCT01563302 is a clinical study titled "Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers". This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of patients with advanced cancers. Eligible patients with DLBCL or other advanced lymphomas will be enrolled into the dose-expansion cohort.
What is the current status of trial NCT01563302?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2012-02-27. Estimated completion is 2016-03-23.
What interventions are being tested in trial NCT01563302?
The interventions under investigation include: IONIS-STAT3Rx (DRUG).
Who is sponsoring clinical trial NCT01563302?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.